Targanta has built a strong senior management team led by Pierre Etienne, M.D., the Company’s Chief Executive Officer. Dr. Etienne joined Targanta in June 2003 after 14 years at Pfizer in Groton, Connecticut, where he served in key executive positions in early clinical research and development operations. The Company’s Chief Scientific Officer is Thomas R. Parr, Jr. Ph.D. Dr. Parr has participated in and led teams in both the discovery and the development of novel anti-infectives, including work on beta-lactams, macrolides, lipopeptides, glycopeptides, protegrins, echinocandins and adaptides. He has both academic and industrial experience. The company’s Vice President of Finance, Christian Belisle, has over 22 years of industry experience. Targanta’s management, its expertise in pre-clinical and clinical matters, and its extensive network of well informed contacts give the Company a competitive edge in licensing activities.